Publications

The breast journal

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

21-05-2013

Lung cancer (Amsterdam, Netherlands)

Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy.

01-05-2013

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Optical sensing for tumor detection in the liver.

01-01-2013

Breast cancer research and treatment

Diffuse reflectance spectroscopy: towards clinical application in breast cancer.

01-01-2013

Breast cancer research and treatment

SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.

01-01-2013

European journal of nuclear medicine and molecular imaging

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.

01-12-2012

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Radioguided occult lesion localisation (ROLL) in breast-conserving surgery after neoadjuvant chemotherapy.

01-12-2012

American journal of nuclear medicine and molecular imaging

Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist.

08-11-2012

Clinical lung cancer

Diffuse reflectance spectroscopy: a new guidance tool for improvement of biopsy procedures in lung malignancies.

01-11-2012

Breast cancer research and treatment

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

01-11-2012

Annals of oncology : official journal of the European Society for Medical Oncology

Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.

01-09-2012

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Pre-treatment imaging and pathology characteristics of invasive breast cancers of limited extent: potential relevance for MRI-guided localized therapy.

01-07-2012

Cancer research

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

01-05-2012

Breast cancer research and treatment

Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.

01-04-2012

Breast cancer research and treatment

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

01-02-2012

Breast cancer research : BCR

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.

27-10-2011

Nature communications

Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity.

25-10-2011

Translational oncology

Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC.

01-08-2011

Annals of oncology : official journal of the European Society for Medical Oncology

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

01-07-2011

Disease models & mechanisms

Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.

01-05-2011

Annals of oncology : official journal of the European Society for Medical Oncology

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

01-04-2011

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.

20-02-2011

Genes, chromosomes & cancer

Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.

01-02-2011

British journal of cancer

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

07-12-2010

Breast cancer research and treatment

A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results.

01-12-2010

Annals of surgical oncology

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

01-09-2010

Annals of surgical oncology

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

01-05-2010

Annals of surgery

MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy.

01-04-2010

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.

01-04-2010

Annals of oncology : official journal of the European Society for Medical Oncology

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy.

01-03-2010

Annals of surgery

Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.

01-03-2010

Breast cancer research and treatment

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.

01-02-2010

Annals of oncology : official journal of the European Society for Medical Oncology

The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.

01-01-2010

Breast cancer research and treatment

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

01-01-2010

Breast cancer research and treatment

Validation of 70-gene prognosis signature in node-negative breast cancer.

01-10-2009

European journal of cancer (Oxford, England : 1990)

Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer.

01-09-2009

Breast cancer research and treatment

The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study.

01-07-2009

American journal of surgery

Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy.

01-07-2009

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: lasting local control and acceptable morbidity.

01-05-2009

Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society

Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels.

01-04-2009

Nederlands tijdschrift voor geneeskunde

[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].

15-11-2008

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.

20-09-2008

The Lancet. Oncology

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

01-12-2007

Molecular biology of the cell

A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.

01-04-1996

British journal of cancer

Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation.

01-02-1996

Biochemical Society transactions

Involvement of the cell surface-bound mucin, episialin/MUC1, in progression of human carcinomas.

01-11-1995

The Journal of cell biology

Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

01-04-1995

Cancer letters

Is episialin/MUC1 involved in breast cancer progression?

23-03-1995

The Journal of cell biology

The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction.

01-12-1994

Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer.

Improved identification of peripheral lung tumors by using diffuse reflectance and fluorescence spectroscopy.

Optical sensing for tumor detection in the liver.

Diffuse reflectance spectroscopy: towards clinical application in breast cancer.

SERPINA6, BEX1, AGTR1, SLC26A3, and LAPTM4B are markers of resistance to neoadjuvant chemotherapy in HER2-negative breast cancer.

Association of primary tumour FDG uptake with clinical, histopathological and molecular characteristics in breast cancer patients scheduled for neoadjuvant chemotherapy.

Radioguided occult lesion localisation (ROLL) in breast-conserving surgery after neoadjuvant chemotherapy.

Non-invasive longitudinal imaging of tumor progression using an (111)indium labeled CXCR4 peptide antagonist.

Diffuse reflectance spectroscopy: a new guidance tool for improvement of biopsy procedures in lung malignancies.

Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.

Clinical correlates of 'BRCAness' in triple-negative breast cancer of patients receiving adjuvant chemotherapy.

Pre-treatment imaging and pathology characteristics of invasive breast cancers of limited extent: potential relevance for MRI-guided localized therapy.

Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.

Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.

Quantitative copy number analysis by Multiplex Ligation-dependent Probe Amplification (MLPA) of BRCA1-associated breast cancer regions identifies BRCAness.

Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity.

Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC.

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.

Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice.

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.

Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype.

Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.

Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.

A practical approach to manage additional lesions at preoperative breast MRI in patients eligible for breast conserving therapy: results.

The relevance of breast cancer subtypes in the outcome of neoadjuvant chemotherapy.

Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature.

MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy.

The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.

A simple system for grading the response of breast cancer to neoadjuvant chemotherapy.

Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.

The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.

The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.

Validation of 70-gene prognosis signature in node-negative breast cancer.

Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer.

The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study.

Accurate axillary lymph node dissection is feasible after neoadjuvant chemotherapy.

Extensive soft tissue resection with autologous tissue closure for locally recurrent breast cancer: lasting local control and acceptable morbidity.

Expression of insulin-like growth factor system components in colorectal tissue and its relation with serum IGF levels.

[Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy].

Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).

A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.

Immunoscintigraphy of small-cell lung cancer xenografts with anti neural cell adhesion molecule monoclonal antibody, 123C3: improvement of tumour uptake by internalisation.

Involvement of the cell surface-bound mucin, episialin/MUC1, in progression of human carcinomas.

Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Is episialin/MUC1 involved in breast cancer progression?

The mucin epiglycanin on TA3/Ha carcinoma cells prevents alpha 6 beta 4-mediated adhesion to laminin and kalinin and E-cadherin-mediated cell-cell interaction.

This site uses cookies